Convalescent Plasma: A Controversial COVID-19 Treatment

This chapter explores the FDA's emergency use authorization of convalescent plasma for COVID-19, detailing how it utilizes antibodies from recovered individuals to aid patient recovery. It critically examines the claims made by government officials about its effectiveness while addressing concerns over the validity of the data supporting such claims. The discussion also highlights the broader implications of this treatment on clinical trials and the risks associated with plasma transfusions in the context of public health.